Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 144Recruiting 77Terminated 40Active not recruiting 28Unknown 26Withdrawn 10Not yet recruiting 7Enrolling by invitation 2Suspended 1Available 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 10Thoracic 2Sarcoma 1Other solid neoplasm 1Other 1Head & Neck 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Lung Neoplasms 26Small Cell Lung Carcinoma 7Breast Neoplasms 5Pulmonary Disease, Chronic Obstructive 4Neoplasms 3Melanoma 3Disease 3Brain Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Mesothelioma 2Lymphoma 2Lung Diseases 2Lung Cancer Screening 2Liver Neoplasms 2Kidney Neoplasms 2Hypoxia 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Cardiovascular Diseases 2Arthritis, Rheumatoid 2Anxiety Disorders 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Enrolling by invitation × Esophageal Neoplasms × Thoracic × Clear all
NCT06603987 2025-11-19

Using CICS-1 and SPM-011 and ï¼»18Fï¼½FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA

Stella Pharma Corporation

Phase 1/2 Enrolling by invitation
30 enrolled
BreastGastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neurofibrosarcoma

NCT06690216 2025-03-30

PD-L1-PET

Shandong Cancer Hospital and Institute

Phase 1/2 Enrolling by invitation
100 enrolled
CNSGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡